Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

BACKGROUND: Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug’s survival benefits is challenging because clinical responses are rarely measurable during treatment. In this study,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Cancer
Huvudupphovsmän: Hayashi, Tomoyuki, Yamashita, Taro, Terashima, Takeshi, Suda, Tsuyoshi, Okada, Hikari, Asahina, Yoshiro, Hayashi, Takehiro, Hara, Yasumasa, Nio, Kouki, Sunagozaka, Hajime, Takatori, Hajime, Arai, Kuniaki, Sakai, Yoshio, Yamashita, Tatsuya, Mizukoshi, Eishiro, Honda, Masao, Kaneko, Shuichi
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738185/
https://ncbi.nlm.nih.gov/pubmed/29258450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3889-x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk